Medical Condition News

RSS

PharmaEngine presents PEP02 phase II studies in gastric and pancreatic cancers at ASCO 2011

PharmaEngine, Inc. announced today that two phase II studies of PEP02 (liposome irinotecan) in gastric and pancreatic cancer studies were presented at the 2011 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO) in San Francisco, CA, USA.

25 Jan 2011

Eisai to seek marketing authorization for perampanel in the U.S. and EU

Eisai announced today that it will submit Marketing Authorization Applications in the United States and the European Union for the investigational compound perampanel (E2007) based on the results of three Phase III pivotal studies. Perampanel is a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered and being developed by Eisai for adjunctive treatment of partial onset seizures in patients with epilepsy.

25 Jan 2011

New study on pain-relieving effect of transcutaneous Vagus Nerve Stimulation

The medical device company cerbomed cooperated with the Clinic for Psychiatry and Psychotherapy of the University of Regensburg 2010 on a randomized, controlled study into somatosensory pain processing. The study, lead by Prof. Dr. Peter Eichhammer and Dr. Volker Busch, aimed to judge the pain-relieving effect of transcutaneous Vagus Nerve Stimulation (t-VNS).

25 Jan 2011

New study: Workplace's key employees may experience high levels of job stress

A workplace's key employees may be at the greatest risk of experiencing high levels of work stress, according to a new study by the Centre for Addiction and Mental Health.

25 Jan 2011

Scientists to develop enzyme that protects against nerve agents

Protection against nerve gas attack is a significant component of the defense system of many countries around the world. Nerve gases are used by armies and terrorist organizations, and constitute a threat to both the military and civilian populations, but existing drug solutions against them have limited efficiency.

25 Jan 2011

Glioblastoma's molecular flexibility helps resist nearly all treatment efforts

Glioblastoma, the most common and lethal form of brain cancer and the disease that killed Massachusetts Senator Ted Kennedy, resists nearly all treatment efforts, even when attacked simultaneously on several fronts. One explanation can be found in the tumor cells' unexpected flexibility, discovered researchers at the Salk Institute for Biological Studies.

25 Jan 2011

Composer Fr-d-ric Chopin probably had temporal lobe epilepsy

The composer Fr-d-ric Chopin, who regularly hallucinated, probably had temporal lobe epilepsy throughout his short life, reveals research published online in Medical Humanities. Hallucinations typically feature in seizure disorders, they say.

25 Jan 2011

World's largest sterile compounding center for oncology patients

Health Robotics today announced the official opening and live operation of the largest Sterile Compounding Center for Oncology patients in the world. Akdeniz University Hospital in Antalya (Turkey) compounds 90% of its 80.000 annual chemotherapy intravenous doses with 4 CytoCare robots and related Health Robotics' technology, or an average of 325 patient doses per 6-hour work cycle.

25 Jan 2011

FDA approves IDE Supplement for third patient allotment in HeartWare Ventricular Assist System ADVANCE trial

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration has approved an IDE Supplement that allows HeartWare to enroll a third allotment, of 94 additional patients, in its "ADVANCE" bridge-to-transplant clinical trial under a Continued Access Protocol (CAP).

25 Jan 2011

St. Georg Hospital performs two live procedures using Endoscopic Ablation System

CardioFocus announced that two "live cases" using its Endoscopic Ablation System were recently conducted. The first live case was a satellite transmission performed at Centro Cardiologico Monzino in Milan, Italy; broadcast to the 16th Annual Boston Symposium on Atrial Fibrillation in Boston, MA.

25 Jan 2011

Eisai's eritoran ACCESS study in severe sepsis does not meet primary endpoint

Based on the preliminary findings from the ACCESS (A Controlled Comparison of Eritoran and Placebo in Patients with Severe Sepsis) trial, Eisai Inc. announced today that the company will not submit marketing authorization applications to regulatory authorities in the United States, the European Union and Japan by the end of the fiscal year (March 31, 2011), as previously planned.

25 Jan 2011

LHSC performs complicated aortic valve bypass surgery using Correx AVB device

Doctors at London Health Sciences Centre (LHSC) are the first in the world to use a new implantable surgical device that promises to revolutionize aortic valve bypass surgery.

25 Jan 2011

Diamyd Medical to report European Phase III trial results for type 1 diabetes

Diamyd Medical's President and CEO Elisabeth Lindner states in the CEO comments in today's quarterly report that the Company expects to begin reporting the results from the European Phase III trial in type 1 diabetes as planned in late spring 2011.

25 Jan 2011

Patients with chronic depression can benefit from pioneering neurosurgical treatment

Pioneering neurosurgical treatment, a world first in Bristol, which very accurately targets brain networks involved in depression, could help people who suffer with severe and intractable depression.

25 Jan 2011

Researchers discover new treatment for difficult-to-control high blood pressure

Researchers were surprised to discover what may be a potential new treatment for difficult-to-control high blood pressure, according to a case report published in the January 25, 2011, print issue of Neurology, the medical journal of the American Academy of Neurology.

25 Jan 2011

RRD enters partnership with NIH Therapeutics for Rare and Neglected Diseases program

RRD International, a strategy-driven biotech and pharmaceutical product development company, announced today that it has entered into a partnership with the National Institutes of Health (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program as a regulatory support and development partner.

25 Jan 2011

Promising results from TheraTears Nutrition pilot trial in dry eye patients

Advanced Vision Research, Inc. today announced the publication in the journal Cornea of promising results from a pilot trial of dry eye patients taking TheraTears® Nutrition. The study demonstrated a reduction in dry eye symptoms and an increase in tear volume and tear flow for those patients taking TheraTears® Nutrition, an optimized blend of medical grade essential omega-3 oils, including eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and flaxseed oil.

25 Jan 2011

Chiropractic treatment helps female Army Brigadier General to battle against fibromyalgia

After 27 years of service, decorated U.S. Army Brigadier General Becky Halstead (Retired), the first female West Point graduate in U.S. history to command at the strategic level in Iraq and Afghanistan, decided to retire after being diagnosed with fibromyalgia - a medically unexplained syndrome affecting the muscles and connective tissues.

25 Jan 2011

New study finds unrealistic optimism prevalent among participants in early-phase cancer trials

Can optimism be ethically problematic? Yes, according to a new study, which found unrealistic optimism prevalent among participants in early-phase cancer trials and suggested that it may compromise informed consent.

25 Jan 2011

p38-targeted compounds hold promise for Alzheimer's disease treatment

Linda J. Van Eldik, director of the University of Kentucky Sanders-Brown Center on Aging, has been awarded a $750,000 grant to further her research into a possible treatment for Alzheimer's disease. The grant is from the Edward N. And Della L. Thome Memorial Foundation, and was one of only eight Awards in Alzheimer's Disease Drug Discovery Research to be given in the U.S. in 2010.

25 Jan 2011

Medical Condition News

PharmaEngine presents PEP02 phase II studies in gastric and pancreatic cancers at ASCO 2011

Eisai to seek marketing authorization for perampanel in the U.S. and EU

New study on pain-relieving effect of transcutaneous Vagus Nerve Stimulation

New study: Workplace's key employees may experience high levels of job stress

Scientists to develop enzyme that protects against nerve agents

Glioblastoma's molecular flexibility helps resist nearly all treatment efforts

Composer Fr-d-ric Chopin probably had temporal lobe epilepsy

World's largest sterile compounding center for oncology patients

FDA approves IDE Supplement for third patient allotment in HeartWare Ventricular Assist System ADVANCE trial

St. Georg Hospital performs two live procedures using Endoscopic Ablation System

Eisai's eritoran ACCESS study in severe sepsis does not meet primary endpoint

LHSC performs complicated aortic valve bypass surgery using Correx AVB device

Diamyd Medical to report European Phase III trial results for type 1 diabetes

Patients with chronic depression can benefit from pioneering neurosurgical treatment

Researchers discover new treatment for difficult-to-control high blood pressure

RRD enters partnership with NIH Therapeutics for Rare and Neglected Diseases program

Promising results from TheraTears Nutrition pilot trial in dry eye patients

Chiropractic treatment helps female Army Brigadier General to battle against fibromyalgia

New study finds unrealistic optimism prevalent among participants in early-phase cancer trials

p38-targeted compounds hold promise for Alzheimer's disease treatment

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest News